This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.
Jeuti Talukdar,
- Researcher, Department of Pharmacy, CT Institute of Pharmaceutical Sciences, Lambri, Punjab, India
Abstract
Lower respiratory tract infections (LRTIs) remain one of the leading causes of morbidity and hospitalization worldwide, particularly among older adults, immunocompromised individuals, and patients with chronic respiratory disorders. These infections include conditions such as community-acquired pneumonia, hospital-acquired pneumonia, bronchitis, and acute infective exacerbations of chronic lung disease, all of which often require rapid clinical intervention. Because microbiological confirmation of the causative pathogen frequently takes 48–72 hours, clinicians generally initiate empirical antibiotic therapy at the time of admission to prevent disease progression and reduce mortality. In many tertiary care hospitals, this empirical treatment commonly relies on broad- spectrum antibiotics to ensure coverage against a wide range of suspected bacterial pathogens, including resistant organisms. Although this approach is clinically justified during the initial management phase, prolonged or inappropriate use of broad-spectrum agents contributes significantly to antimicrobial resistance, increased treatment costs, adverse drug reactions, and disruption of normal microbial flora. This study evaluates the burden of empirical antibiotic therapy in lower respiratory tract infections within a tertiary care setting, with particular emphasis on prescribing trends, the predominance of broad-spectrum antimicrobial agents, and the importance of antibiotic de-escalation after microbiological or clinical reassessment. De-escalation strategies are essential for optimizing therapy, improving patient outcomes, and supporting antimicrobial stewardship practices. A prospective observational study was carried out over a six-month period in a tertiary care teaching hospital located in Jalandhar to evaluate antibiotic prescribing practices among patients diagnosed with respiratory tract infections. The study included 100 hospitalized patients who met predefined clinical and diagnostic criteria for lower respiratory tract infections, including pneumonia, acute bronchitis, and infective exacerbations of chronic respiratory diseases. Demographic details, clinical presentation, laboratory findings, microbiological reports, and antibiotic prescriptions were systematically recorded from patient case sheets and treatment charts throughout the hospital stay. Particular emphasis was placed on identifying the empirical antibiotics prescribed at admission and classifying them according to their antimicrobial spectrum as broad-spectrum or narrow-spectrum agents. The study also assessed the prevalence and distribution of lower respiratory tract infections among different age groups and clinical categories. Subsequent changes made to the initial antibiotic regimen were carefully documented, including escalation to broader agents when clinical response was inadequate and de-escalation to narrower-spectrum therapy once microbiological culture reports or clinical improvement supported targeted treatment. This observational approach provided valuable insight into real-world prescribing behavior, antibiotic utilization trends, and the practical implementation of antimicrobial stewardship principles in the management of respiratory infections in a tertiary care setting. The study identified a heavy burden of LRTIs, which constituted 87% of all cases , with pneumonia being the leading diagnosis (30%). Empirical therapy was heavily reliant on broad-spectrum antibiotics, which were prescribed in 89% of cases. This predominance was driven by a significant diagnostic gap, as 80% of cultures yielded no identifiable microorganism. Despite the high initial burden of broad-spectrum use, antibiotic de- escalation was successfully implemented in 46% of patients, primarily through dose reduction and spectrum narrowing. Conclusions: The predominance of broad-spectrum antibiotic usage reflects the necessity of empirical coverage for LRTIs in elderly and comorbid populations where pathogen identification is often absent. While this “burden of empirical therapy” is high, it is effectively managed through responsive de-escalation strategies, highlighting the critical role of antimicrobial stewardship in balancing empirical needs with resistance prevention.
Keywords: Empirical Therapy; Broad-Spectrum Antibiotics; Lower Respiratory Tract Infections; Antibiotic Stewardship; De-escalation
Jeuti Talukdar. THE BURDEN OF EMPIRICAL THERAPY: ANALYZING THE PREDOMINANCE OF BROAD-SPECTRUM ANTIBIOTIC USAGE IN LOWER RESPIRATORY TRACT INFECTIONS. International Journal of Antibiotics. 2026; 03(02):-.
Jeuti Talukdar. THE BURDEN OF EMPIRICAL THERAPY: ANALYZING THE PREDOMINANCE OF BROAD-SPECTRUM ANTIBIOTIC USAGE IN LOWER RESPIRATORY TRACT INFECTIONS. International Journal of Antibiotics. 2026; 03(02):-. Available from: https://journals.stmjournals.com/ijab/article=2026/view=248510
References
1. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis Christopher J. L. Murray, Kevin S. Ikuta, Farah Sharara, et al. Global burden of
bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022;399(10325):629–655. doi:10.1016/S0140-6736(21)02724-0.
2. World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report 2022. Geneva: WHO; 2023.
3. Kenneth D. Reed, et al. Respiratory tract infections: a clinical approach. In: Molecular Medical Microbiology. 2nd ed. London: Elsevier; 2014. p.1499–1506.
4. Richard G. Wunderink, Arjun Srinivasan, Philip S. Barie, et al. Antibiotic stewardship in the intensive care unit: an official American Thoracic Society workshop report.
Annals of the American Thoracic Society. 2020;17(5):531–540.
5. Joshua P. Metlay, Grant W. Waterer. Update in adult community-acquired pneumonia: key points from the 2019 ATS/IDSA guidelines and 2023 updates. Annals of Internal Medicine. 2023;176(5):669–679.
6. Abdulrahman Alanazi, Raghad Almuhaya, Maha Almohaimeed, et al. Impact of antibiotic de-escalation on antibiotic consumption, length of hospitalization, mortality,
and cost: a systematic review and meta-analysis. Pharmacoepidemiology. 2023;2(3):289–306.
7. William L. Hamilton, Sara M. Pires, Sarah Lippett, et al. The impact of diagnostic microbiology on de-escalation of antimicrobial therapy in hospitalized adults. BMC
Infectious Diseases. 2020;20:1–7.
8. LRTI Collaborators. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021. The Lancet Infectious Diseases. 2024;24:in press.
9. Carlos Rojas-Moreno. Antibiotic de-escalation in culture-negative healthcare- associated pneumonia. University of Missouri; academic clinical report.
10. Antoni Torres, Marcos I. Restrepo, et al. International ERS/ESICM/ESCMID/ALAT guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia. European Respiratory Journal. 2017;50(3):1700582.
11. John E. McGowan Jr.. Antimicrobial stewardship—the state of the art in 2024. Clinical Infectious Diseases. 2024;78(2):215–223.
12. Derek C. Angus, Tom van der Poll. Severe lower respiratory tract infection and sepsis management in adults. New England Journal of Medicine. 2023;389(8):745–756.
International Journal of Antibiotics
| Volume | 03 |
| 02 | |
| Received | 27/02/2026 |
| Accepted | 29/04/2026 |
| Published | 01/07/2026 |
| Publication Time | 124 Days |
Login
PlumX Metrics